Pacemakers Market Report 2025

This Pacemakers report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The pacemakers market size has grown strongly in recent years. It will grow from $5.42 billion in 2024 to $5.72 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to aging population, cardiovascular diseases, lifestyle-related health issues, regulatory approvals, heart attack survivors.

The pacemakers market size is expected to see strong growth in the next few years. It will grow to $7.78 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to telemedicine, public and private healthcare investment, pediatric and neonatal care, surgical techniques, miniaturization and leadless devices. Major trends in the forecast period include artificial intelligence (ai), wearable health tech, remote programming, electrophysiology procedures, technological advancements.

The rising incidence of cardiovascular diseases is driving the growth of the pacemaker market in the future. Cardiovascular diseases encompass conditions that impact the heart and blood vessels. Drug discovery technologies are employed to identify new medications for these diseases. Pacemakers consist of flexible, insulated wires that assist in managing cardiovascular conditions by regulating irregular heart rhythms. For instance, in January 2024, the American Heart Association, a US-based nonprofit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, representing a 4% rise from the previous year's rate of 224.4 per 100,000, following a 4.6% increase in 2023, marking the first rise in these rates seen in many years. Consequently, the growing prevalence of cardiovascular diseases is expected to boost the pacemaker market.

The expansion of the geriatric population is another factor expected to contribute to the growth of the pacemaker market. With age, the risk of heart conditions such as arrhythmias, atrial fibrillation, and bradycardia increases, necessitating pacemaker implantation. A report from the World Health Organization in October 2022 highlighted that by 2030, one in six people globally is expected to be 60 or older, with the global population of individuals aged 80 or older increasing by 426 million between 2020 and 2050. This demographic shift is a significant driver for the growth of the pacemaker market.

Innovation in product development is a notable trend in the pacemaker market, with major companies introducing novel products to cater to diverse customer needs and enhance revenue. For example, in July 2023, Abbott, a US-based medical device company, obtained FDA approval for the AVEIR dual chamber (DR) leadless pacemaker system. This innovative system, enabled by Abbott's i2i communication technology, facilitates synchronized cardiac pacing between two leadless pacemakers based on a patient's clinical requirements, expanding access to leadless pacing for a larger population in the United States.

Major companies in the pacemaker market are developing advanced products such as miniaturized pacemakers to further broaden their customer base and increase sales. In May 2023, Medtronic PLC, a US-based medical device company, received FDA approval for the Micra AV2 and Micra VR2, recognized as the world's smallest pacemakers. These miniaturized, leadless pacemakers offer extended battery life and simplified programming, aiming to reduce complications compared to traditional pacemakers. The Micra AV2 and Micra VR2 contribute to enhanced patient outcomes with their longer battery life and advanced algorithms for autonomous programming of atrioventricular synchrony.

In February 2023, Royal Philips, a health technology company based in the Netherlands, announced a long-term strategic partnership with TriHealth. This collaboration aims to incorporate Philips’ extensive cardiology solutions into TriHealth's new Heart & Vascular Institute at Bethesda North Hospital and the Harold and Eugenia Thomas Comprehensive Care Center. The partnership is designed to enhance cardiac care services, meet community health commitments, coordinate health services among providers, and educate future healthcare professionals. TriHealth, a US-based organization, specializes in integrated healthcare delivery systems, including pacemakers.

Major companies operating in the pacemakers market include Boston Scientific Corporation, ZOLL Medical Corporation, Medtronic plc Biotronik Medical Devices India Pvt ltd., MicroPort Scientific Corporation, Cook Medical Incorporated, MEDICO S.p.A., Shree Pacetronix Ltd., Oscor Inc., Osypka Medical GmbH, Abbott Laboratories, LivaNova PLC, Lepu Medical Technology(Beijing)Co Ltd., Cordis Inc., Vitatron Holding B.V., Integer Holdings Corporation, Zoll Medical Corporation, Synapse Biomedical Inc., Pacetronix Limited, Sorin Group Italia S.r.l., Galix Biomedical Instrumentation Inc., Imricor Medical Systems Inc., Sterimed Group, Edwards Lifesciences Corporation, SMT Medical GmbH & Co. KG, Spacelabs Healthcare Inc., BioTrace Medical Inc.

North America was the largest region in the pacemaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pacemaker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pacemaker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Pacemakers are small devices implanted in the chest to regulate the heartbeat, specifically to prevent the heart from beating too slowly. They are utilized in the treatment of conditions such as fainting spells, congestive heart failure, and hypertrophic cardiomyopathy.

The main types of pacemakers include MRI-compatible pacemakers and conventional pacemakers. MRI-compatible pacemakers are devices that present no known hazards in specified MRI environments, subject to specific device and MRI scanner conditions. These pacemakers employ various technologies, such as single-chamber pacemakers, dual-chamber pacemakers, and biventricular or CRT (cardiac resynchronization therapy) pacemakers. They differ in implantability, with options including implantable pacemakers and external pacemakers. The applications of pacemakers encompass congestive heart failure, arrhythmias, bradycardia, and tachycardia, serving various end users such as hospitals, cardiac care centers, ambulatory surgical centers, and others.

The pacemaker market research report is one of a series of new reports that provides pacemaker market statistics, including pacemaker industry global market size, regional shares, competitors with a pacemaker market share, detailed pacemaker market segments, market trends and opportunities, and any further data you may need to thrive in the pacemakers industry. This pacemaker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pacemaker market consists of sales of leadless pacemakers and transvenous peacemakers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.